SpectraCure AB (publ) (STO:SPEC)
Sweden
· Delayed Price · Currency is SEK 0.7720
-0.0380 (-4.69%)
May 13, 2025, 2:59 PM CET
SpectraCure AB Company Description
SpectraCure AB (publ) engages in the development of cancer treatment system.
It develops Q-PRO, a laser device; and IDOSE software with interstitial photodynamic therapy system for the treatment of prostate cancer.
The company was incorporated in 2003 and is based in Lund, Sweden.
SpectraCure AB (publ)
| Country | Sweden |
| Founded | 2003 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Masoud Khayyami |
Contact Details
Address: Gasverksgatan 1 Lund, 222 29 Sweden | |
| Phone | 46 46 16 20 70 |
| Website | spectracure.com |
Stock Details
| Ticker Symbol | SPEC |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0007158118 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Dr. Masoud Khayyami Ph.D. | Interim Chief Executive Officer and Director |
| Henrik Ljung | Chief Financial Officer |
| Dr. Johannes Swartling Ph.D. | Chief Technology Officer |
| Mirjam Johansson | Administrative Manager |
| Kristina Holst | Head of Clinical Affairs |